Goldman Sachs Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $25
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical, Inc. RARE | 0.00 |
Goldman Sachs analyst Salveen Richter downgrades Ultragenyx Pharmaceutical (NASDAQ:
RARE) from Buy to Neutral and lowers the price target from $61 to $25.
